Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19
Basel, 07 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has extended the marketing authorisation for Actemra ®/RoActemra® (tocilizumab) to include the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.1 This decision comes just hours after the recommendation by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), reflecting the urgent need for Actemra/RoActemra as a potential treatment option during the COVID-19 public health emergency. (Source:...
Source: Roche Investor Update - December 7, 2021 Category: Pharmaceuticals Source Type: news

Roche completed the repurchase of Roche shares from Novartis
Basel, 6 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it completed the repurchase of Roche shares that had been held by Novartis. On 4 November 2021, Roche and Novartis had announced this repurchase. The Extraordinary General Meeting of Roche Holding Ltd passed the resolutions required for the repurchase and the capital reduction on 26 November 2021. In accordance with the respective resolution of the Extraordinary General Meeting of 26  November 2021, the 53,309,000 shares have now been repurchased by Roche and the corresponding consideration has been transferred to Novartis. The repurchase...
Source: Roche Investor Update - December 6, 2021 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Actemra/RoActemra to treat patients with severe COVID-19
Basel, 06 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended extending the marketing authorisation for Actemra®/RoActemra® (tocilizumab) to include the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. A final decision regarding the approval of Actemra/RoActemra is expected from the European Commission in the near future. (Source: Roche Investor Update)
Source: Roche Investor Update - December 6, 2021 Category: Pharmaceuticals Source Type: news

Roche to launch SARS-CoV-2 & Flu A/B Rapid Antigen Test in countries accepting the CE Mark to enable rapid differentiation of viral respiratory infections
Basel, 6 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced its plans to launch the SARS-CoV-2& Flu A/B Rapid Antigen Test for professional use in markets accepting the CE Mark by the beginning of January. Roche also intends to file for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) in early 2022. (Source: Roche Investor Update)
Source: Roche Investor Update - December 6, 2021 Category: Pharmaceuticals Source Type: news

Changes in the Board of Directors
Basel, 3 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that at its December meeting the Board of Directors of Roche Holding Ltd has approved first proposals to the Annual General Meeting (AGM) scheduled for 15 March 2022. (Source: Roche Investor Update)
Source: Roche Investor Update - December 3, 2021 Category: Pharmaceuticals Source Type: news

Reminder: Invitation to Roche ’s virtual analyst event during ESMO IO
  (Source: Roche Investor Update)
Source: Roche Investor Update - December 3, 2021 Category: Pharmaceuticals Source Type: news

Roche has rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant
Basel, 3 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and TIB Molbiol, a newly acquired subsidiary within the Roche Diagnostics division, have added three additional Research Use Only (RUO) test kits for the detection of mutations present in the novel B.1.1.529 Omicron SARS-CoV-2 variant: VirSNip SARS Spike ins214EPE (RUO), VirSNiP SARS-CoV-2 Spike S371L S373P (RUO), VirSNip SARS Spike E484A (RUO). The World Health Organization (WHO) has classified the recently emerged SARS-CoV-2 variant, Omicron (B.1.1.529), as a COVID-19 variant of concern (VOC).The VirSNiP variant kits allow differentiation between unique mutation...
Source: Roche Investor Update - December 3, 2021 Category: Pharmaceuticals Source Type: news

Roche completes purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases
Basel, 1 December  2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced it has completed its share purchase agreement to acquire 100 percent of the outstanding shares of TIB Molbiol Group. TIB Molbiol will continue to operate as a subsidiary within the Diagnostics division. Roche and TIB Molbiol will build on t heir capabilities for the rapid development of assays for emerging pathogens and potential health threats, such as infectious diseases. (Source: Roche Investor Update)
Source: Roche Investor Update - December 1, 2021 Category: Pharmaceuticals Source Type: news

Roche Extraordinary General Meeting 2021
Basel, 26 November 2021 – On 4 November 2021, Roche (SIX: RO, ROG; OTCQX: RHHBY) had announced its agreement with Novartis Holding AG (Novartis) regarding the repurchase of the equity stake held by Novartis in Roche. At the same time, Roche had informed that the repurchase was conditional upon, inter alia, the approval b y an Extraordinary General Meeting of Roche Holding Ltd of the capital reduction by cancellation of the shares to be repurchased from Novartis and of the interim financial statements prepared for the purpose of this transaction.At today's Extraordinary General Meeting of Shareholders, the Board of Di...
Source: Roche Investor Update - November 26, 2021 Category: Pharmaceuticals Source Type: news

Roche to present new pivotal data at ASH 2021 from broad and comprehensive portfolio, challenging treatment standards for people with blood disorders
Basel, 23 November 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its extensive haematology portfolio will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition from 11-14 December 2021. Roche molecules will be featured in more than 90 abstracts, including 17 oral presentations, showcasing new immunotherapies, unique treatment combinations, the application of novel endpoints, and fixed-duration regimens.Results from three pivotal studies will be featured: (Source: Roche Investor Update)
Source: Roche Investor Update - November 23, 2021 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer
Basel, 19 November 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) has granted conditional marketing authorisation for Gavreto ® (pralsetinib) as a monotherapy for the treatment of adults with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor. Gavreto is the first and only precision medicine approved in the European Union (EU) for th e first-line treatment of people with RET fusion-positive advanced NSCLC.1 (Source: Roche Investor Update)
Source: Roche Investor Update - November 19, 2021 Category: Pharmaceuticals Source Type: news

Roche launches cobas 5800, a new molecular diagnostics system to expand access to testing and improve patient care
Basel, 18 November 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of thecobas® 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark. Testing is one of the first lines of defense to protect a patient ’s general well-being and is vitally important in quickly guiding their treatment. The cobas 5800 System helps address challenges that laboratories are facing from an increase in patient testing, reimbursement complexities and the need for a more diverse testing menu while providing meaningful and timely results.  “Diagnostics continue to revoluti...
Source: Roche Investor Update - November 18, 2021 Category: Pharmaceuticals Source Type: news

Invitation to Roche ’s virtual event on key hematology data presented at ASH 2021
We are pleased to invite investors and analysts to participate in our virtual event on Wednesday, 15 December, 2021, highlighting Roche data presented at the virtual American Society of Hematology (ASH) 63rd Annual Meeting, from 11-14th December. (Source: Roche Investor Update)
Source: Roche Investor Update - November 16, 2021 Category: Pharmaceuticals Source Type: news

Invitation to Roche ’s virtual analyst event during ESMO IO
  (Source: Roche Investor Update)
Source: Roche Investor Update - November 15, 2021 Category: Pharmaceuticals Source Type: news

Roche ranked as one of the top three most sustainable healthcare companies in the Dow Jones Sustainability Indices for the thirteenth year running
Basel, 15 November 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) has again been recognised as one of the most sustainable companies in the Pharmaceuticals index of the Dow Jones Sustainability Indices (DJSI). This is based on an in-depth analysis of economic, social and environmental performance. The DJSI family of indices serves as a benchmark for investors who integrate sustainability considerations into their portfolios.Roche has maintained its leadership through its sustainability strategy, which is fully embedded in the company ’s business and culture.“We are proud of being recognised once again for our consis...
Source: Roche Investor Update - November 15, 2021 Category: Pharmaceuticals Source Type: news

Ronapreve approved by European Commission to treat non-hospitalised COVID-19 patients and for prophylaxis of the disease
Basel, 12 November 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted a marketing authorisation for Ronapreve ™ (casirivimab and imdevimab), for treating COVID-19 in adults and adolescents (from 12 years of age and weighing at least 40 kilograms) who do not require supplemental oxygen and who are at increased risk of their disease becoming severe, and for preventing COVID-19 in people aged 12 years and ol der weighing at least 40 kilograms (pre- or post-exposure prophylaxis). This decision follows one day after the positive opinion by the European Medicines Agency's (EM...
Source: Roche Investor Update - November 12, 2021 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Ronapreve to treat non-hospitalised COVID-19 patients and for prophylaxis of the disease
Basel, 11 November 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of the antibody combination, Ronapreve™ (casirivimab and imdevimab), for treating COVID-19 in adults and adolescents (from 12 years of age and weighing at least 40 kilograms) who do not require supplement al oxygen and who are at increased risk of their disease becoming severe, and for preventing COVID-19 in people aged 12 years and older weighing at least 40 kilograms (pre- or post-exposure prophylaxis). A fin...
Source: Roche Investor Update - November 11, 2021 Category: Pharmaceuticals Source Type: news

New Phase 3 analyses show that a single dose of REGEN-COV (casirivimab and imdevimab) provides long-term protection against COVID-19
Dear Investor,Please find attached a press release from our partner Regeneron regarding new follow-up analyses of the 2069 prevention trial that add to the increasing body of evidence supporting the use of  Ronapreve to prevent COVID-19: (Source: Roche Investor Update)
Source: Roche Investor Update - November 8, 2021 Category: Pharmaceuticals Source Type: news

Ronapreve Approved for Additional Indication as a Preventive Treatment of Symptomatic COVID-19 in Japan
Dear Investor,Please find attached a press release by Chugai:https://www.roche.com/211105eRonapreveApproval.pdf,Do not hesitate to contact us for any further questions.With best regards, (Source: Roche Investor Update)
Source: Roche Investor Update - November 5, 2021 Category: Pharmaceuticals Source Type: news

Ver öffentlichung gemäss Art. 61 Abs. 3 und Abs. 4 der Verordnung der Übernahmekommission über öffentliche Kaufangebote (UEV) durch Roche Holding AG, Basel
Ver öffentlichung gemäss Art. 61 Abs. 3 und Abs. 4 der Verordnung der Übernahmekommission über öffentliche Kaufangebote (UEV) durch Roche Holding AG, Basel (Source: Roche Investor Update)
Source: Roche Investor Update - November 5, 2021 Category: Pharmaceuticals Source Type: news

Publication selon l'art. 61 al. 3 et 4 de l'Ordonnance de la Commission des OPA sur les offres publiques d'acquisition (OOPA) de Roche Holding SA, B âle
– En référence à la décision 795/01 de la Commission des OPA du 4 novembre 2021 dans le cadre de la requête d'Andr é Hoffmann, Marie-Anne Hoffmann, Vera Michalski, Alexander Hoffmann, Frederic Hoffmann, Isabel Hoffmann, Lucas Hoffmann, Marina Hoffmann, Kasia Barbotin- Larrieu, Tatiana Fabre, Andreas Oeri, Catherine Oeri, Sabine Duschmalé, Jörg Duschmalé, Lukas Duschmalé et Stiftung Wolf (Source: Roche Investor Update)
Source: Roche Investor Update - November 5, 2021 Category: Pharmaceuticals Source Type: news

Publication pursuant to Art. 61 para. 3 and 4 of the Ordinance of the Swiss Takeover Board on Public Takeover Offers (TOO) by Roche Holding Ltd, Basel
With respect to the decision 795/01 of the Swiss Takeover Board of 4 November 2021 regarding the request of Andr é Hoffmann, Marie-Anne Hoffmann, Vera Michalski, Alexander Hoffmann, Frederic Hoffmann, Isabel Hoffmann, Lucas Hoffmann, Marina Hoffmann, Kasia BarbotinLarrieu, Tatiana Fabre, Andreas Oeri, Catherine Oeri, Sabine Duschmalé, Jörg Duschmalé, Lukas Duschmalé and Stiftung Wolf (Source: Roche Investor Update)
Source: Roche Investor Update - November 5, 2021 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces the repurchase of the equity stake held by Novartis in Roche
Basel, 4 November 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Novartis have announced today that they agreed on a repurchase by Roche of the 53.3 million Roche shares held by Novartis. The aggregate transaction value is approx. CHF 19 billion. The price per share is CHF 356.9341. It corresponds to the volume weighted average price of the Roche non-voting equity certificates over the last 20 trading days up to and including 2 November 2021. The Board of Directors of Roche has approved the envisaged repurchase, which will be debt-financed by Roche. All shareholders and holders of non-voting equity certificates of Roche ben...
Source: Roche Investor Update - November 4, 2021 Category: Pharmaceuticals Source Type: news

Save the date: Roche Virtual Event – Update following ASH 2021 Wednesday 15th December 2021
(Source: Roche Investor Update)
Source: Roche Investor Update - November 1, 2021 Category: Pharmaceuticals Source Type: news

IMPACT trial data shows clear benefit in using Roche's CINtec PLUS Cytology test for women who are at higher risk of developing cervical cancer
IMPACT trial data shows clear benefit in using Roche'sCINtec PLUS Cytology test for women who are at higher risk of developing cervical cancer (Source: Roche Investor Update)
Source: Roche Investor Update - October 29, 2021 Category: Pharmaceuticals Source Type: news

Roche launches comprehensive genomic profiling kit to expand access to personalised cancer research
Basel, 25 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has launched the AVENIO Tumor Tissue CGP Kit. The Kit complements the current CGP portfolio offered by Roche and Foundation Medicine and allows laboratories to expand their oncology research in-house. Ultimately, a future version of the kit may lead to additional resources for clinicians to use in the diagnosis and treatment of cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - October 25, 2021 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD)
Basel, 22 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Susvimo ™ (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with neovascular or “wet” age-related macular degeneration (nAMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. Neovascular AMD is a potentially blinding condition that requires treatment with eye injections as often as once a month.1,2,3,4 Susvimo, previously called Port Delivery System with ranibizum...
Source: Roche Investor Update - October 22, 2021 Category: Pharmaceuticals Source Type: news

Roche ’s VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq® (atezolizumab)
Basel, 22 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA PD-L1 (SP263) Assay in non- small cell lung cancer (NSCLC) as a companion diagnostic test for Tecentriq, advancing the company's commitment to guide clinical decision making through innovative, high quality assays that improve patient access to personalized healthcare. (Source: Roche Investor Update)
Source: Roche Investor Update - October 22, 2021 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in the first nine months – outlook for 2021 raised
CEO Severin Schwan on the results: “The demand for coronavirus tests remained high in the third quarter due to the Delta variant. (Source: Roche Investor Update)
Source: Roche Investor Update - October 20, 2021 Category: Pharmaceuticals Source Type: news

US FDA approves Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 15 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq ® (atezolizumab) as adjuvant treatment, following surgery and platinum-based chemotherapy, for adults with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-approved test. (Source: Roche Investor Update)
Source: Roche Investor Update - October 15, 2021 Category: Pharmaceuticals Source Type: news

Roche announces PathAI collaboration for artificial intelligence-based digital pathology applications for improved patient care
Basel, 15 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has entered an agreement with PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology. Under the development and distribution agreement, the companies will jointly develop an embedded image analysis workflow for pathologists. This workflow will allow PathAI image analysis algorithms to be accessed within NAVIFY Digital Pathology, the cloud version of Roche ’s uPath enterprise software. This collaboration is now possible through Roche’s Digital Pathology Open Environment, which allows pathologists...
Source: Roche Investor Update - October 15, 2021 Category: Pharmaceuticals Source Type: news

FDA accepts REGEN-COV (casirivimab and imdevimab) for priority review for treatment and prophylaxis of COVID-19
Dear Investor,Please find attached a press release from our partner Regeneron:https://investor.regeneron.com/news-releases/news-release-details/fda-accepts-regen-covr-casirivimab-and-imdevimab-priority-reviewDo not hesitate to contact us for any further questions.With best regards, (Source: Roche Investor Update)
Source: Roche Investor Update - October 14, 2021 Category: Pharmaceuticals Source Type: news

Invitation to Roche ’s Virtual Event " Digitalization along the value chain "
  (Source: Roche Investor Update)
Source: Roche Investor Update - October 14, 2021 Category: Pharmaceuticals Source Type: news

New four-year data show Roche's ENSPRYNG significantly reduces debilitating relapses in people with neuromyelitis optica spectrum disorder
Basel, 14 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new longer-term efficacy and safety data for ENSPRYNG® (satralizumab). The data show ENSPRYNG has a favourable benefit:risk profile and is effective in reducing relapses over four years of treatment in people with anti-aquaporin-4 antibody (AQP 4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD), a rare debilitating disease that affects the central nervous system. Efficacy and safety results from the open-label extension (OLE) periods of the SAkuraStar and SAkuraSky studies, in addition to the design of SAkuraBONSAI, a new ...
Source: Roche Investor Update - October 14, 2021 Category: Pharmaceuticals Source Type: news

Roche ’s Gazyvaro shorter 90-minute infusion time approved in Europe for people with previously treated or untreated follicular lymphoma
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced European Medicines Agency (EMA) approval of a new, shorter 90-minute Gazyvaro ® (obinutuzumab) infusion time, administered in combination with chemotherapy in patients with previously treated or untreated advanced follicular lymphoma (FL). (Source: Roche Investor Update)
Source: Roche Investor Update - October 14, 2021 Category: Pharmaceuticals Source Type: news

Reminder: Invitation to Roche ’s 3rd Quarter Sales 2021 Webinar
   (Source: Roche Investor Update)
Source: Roche Investor Update - October 13, 2021 Category: Pharmaceuticals Source Type: news

Data up to 8-years for Roche ’s OCREVUS (ocrelizumab) show early and ongoing treatment significantly reduced risk of requiring a walking aid in relapsing multiple sclerosis and disability progression in primary progressive multiple sclerosis
Basel, 13 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new long-term data that reinforce the benefit of early initiation and ongoing treatment of OCREVUS® (ocrelizumab) on disability progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS), as well as safety outcomes for an analysis of shorter 2-hour infusion in minority populations. OCREVUS data from all clinical trials consistently show a favourable benefit-risk profile over eight years. Roche and research partners will also present four late-breaking abstracts to share the latest data regarding COVID-19 and vacci...
Source: Roche Investor Update - October 13, 2021 Category: Pharmaceuticals Source Type: news

Chugai files for additional indications of Ronapreve for prophylaxis and treatment of asymptomatic COVID-19
Dear Investor,Please find attached a press release by Chugai:https://www.roche.com/211011_IR_Chugai_eRonapreve NDA.pdfDo not hesitate to contact us for any further questions.With best regards, (Source: Roche Investor Update)
Source: Roche Investor Update - October 11, 2021 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer’s disease
Basel, 8 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s di sease (AD). This designation is based on data showing that gantenerumab significantly reduced brain amyloid plaque, a pathological hallmark of AD, in the ongoing SCarlet RoAD and Marguerite RoAD open-label extension trials, as well as other studies. Learnings from these studies have been incorporat...
Source: Roche Investor Update - October 8, 2021 Category: Pharmaceuticals Source Type: news

Roche to present new data on OCREVUS in multiple sclerosis and ENSPRYNG in neuromyelitis optica spectrum disorder at ECTRIMS 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS ® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from 13 - 15 October 2021. These data include 38 abstracts highlighting new longer-term efficacy and safety for both OCREVUS and ENSPRYNG, as well as our ongoing efforts to evaluate the impact of the COVID-19 pandemic for people living with MS. Additional data will show how a deeper scientific understanding of MS and NMOSD in diverse patient populations ...
Source: Roche Investor Update - October 5, 2021 Category: Pharmaceuticals Source Type: news

Phase II/III trial shows Ronapreve ™ (casirivimab and imdevimab) significantly reduces viral load within seven days of treatment in patients hospitalised with COVID-19
Basel, 30 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve ™ (casirivimab and imdevimab) in patients hospitalised with COVID-19. The trial met its primary endpoint, showing that Ronapreve significantly reduced viral load within seven days of treatment in patients who had not mounted a natural antibody response of their own (seronegative) and who required low-flow or no supplemental oxygen (p=0.0172). Full results of the study will be presented at ID Week 2021 today. (Source: Roche Investor Update)
Source: Roche Investor Update - September 30, 2021 Category: Pharmaceuticals Source Type: news

Roche presents new data at World Muscle Society (WMS) 2021 highlighting new advances for people living with rare neuromuscular disorders
Basel, 24 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from across its growing neuromuscular portfolio at the World Muscle Society (WMS) Virtual Congress 20 – 24 September 2021. The presentations included additional results from the RAINBOWFISH study, evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic spinal muscular atrophy (SMA) from birth to six weeks of age and data supporting the continued clinical investig ation of gene therapy, SRP-9001, in Duchenne muscular dystrophy (DMD).“These new data for Evrysdi may help extend the potential ben...
Source: Roche Investor Update - September 24, 2021 Category: Pharmaceuticals Source Type: news

Roche launches three respiratory test panels on cobas 6800/8800 Systems in CE markets to help identify multiple pathogens with overlapping symptoms in patients
Basel, 22 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of three molecular PCR diagnostic test panels to simultaneously detect and differentiate common respiratory pathogens:   (Source: Roche Investor Update)
Source: Roche Investor Update - September 22, 2021 Category: Pharmaceuticals Source Type: news

New Phase III data support the benefit of Roche ’s Tecentriq in early-stage lung cancer
Basel, 20 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented new data from the Phase III IMpower010 study at the European Society for Medical Oncology (ESMO) Congress 2021 Presidential Symposium, reinforcing the significant disease-free survival (DFS) benefit offered by Tecentriq ® (atezolizumab) for people with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%. Data from the IMpower010 trial were published simultaneously in The Lancet. In IMpower010, treatment with Tecentriq, following surgery and chemotherapy, reduced the risk of disease re currence or death (DFS) by ...
Source: Roche Investor Update - September 20, 2021 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Gavreto ® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer
Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Gavreto® (pralsetinib) as a monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated w ith a RET inhibitor. (Source: Roche Investor Update)
Source: Roche Investor Update - September 17, 2021 Category: Pharmaceuticals Source Type: news

Roche presents first phase II data on giredestrant, a next generation selective oestrogen receptor degrader, in untreated oestrogen receptor (ER)-positive, early breast cancer
Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced interim data from the randomised phase II coopERA Breast Cancer trial evaluating neoadjuvant treatment with giredestrant (formerly known as GDC-9545), an investigational next generation oral selective oestrogen receptor degrader (SERD), in post-menopausal women with ER-positive, HER2-negative early breast cancer. In the window of opportunity phase, after 14 days of treatment, giredestrant showed a reduction in Ki67, a prognostic marker that measures tumour proliferation, compared to anastrozole (80% versus 67% respectively, p=0.0222). The safety ...
Source: Roche Investor Update - September 17, 2021 Category: Pharmaceuticals Source Type: news

Roche opens access to pathology imaging tools to improve patient care
Basel, 15 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the introduction of theRoche Digital Pathology Open Environment that allows software developers to easily integrate their image analysis tools for tumour tissue with Roche ’s uPath enterprise software, an application for pathologist workflow. This open environment allows for the secure exchange and flow of data so that pathologists can access advanced algorithms from third parties alongside Roche’s menu of artificial intelligence-based image analysis tools. This e nables software developers globally to distribute their digital product...
Source: Roche Investor Update - September 15, 2021 Category: Pharmaceuticals Source Type: news

Roche signs definitive share purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases
Basel, 09 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has signed a definitive share purchase agreement to acquire 100% of the outstanding shares of the TIB Molbiol Group. Closing of the transaction is subject to customary conditions and is expected in the fourth quarter of 2021. (Source: Roche Investor Update)
Source: Roche Investor Update - September 9, 2021 Category: Pharmaceuticals Source Type: news

Roche to present data from industry leading portfolio at ESMO 2021 showing significant progress in early stage and uncommon cancers
Basel, 07 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new oncology data will be presented at the European Society for Medical Oncology (ESMO) Congress, which will be held 16-21 September, 2021. With one of the broadest oncology pipelines and portfolios in the industry, Roche presentations include late-breaking abstracts featuring data in early-stage breast cancer and early-stage lung cancer, and a presentation on cancer of unknown primary (CUP), which has been selected for inclusion in the ESMO Press Programme. (Source: Roche Investor Update)
Source: Roche Investor Update - September 7, 2021 Category: Pharmaceuticals Source Type: news

Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer
Basel, 27 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the company has made the decision to voluntarily withdraw the US accelerated approval for Tecentriq ® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumours express PD-L1, as determined by a US Food and Drug Administration (FDA)-approved test. Roche made this decision following consultation with the US FDA, based on the agency’s assessment of the current mTN...
Source: Roche Investor Update - August 27, 2021 Category: Pharmaceuticals Source Type: news